Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

Regression Models and Life-Tables

1972 • 27,145 citations

Bayesian Data Analysis

1995 • 14,293 citations

Robust Locally Weighted Regression and Smoothing Scatterplots

1979 • 10,049 citations

Modeling Survival Data: Extending the Cox Model

2000 • 7,620 citations

Evaluation of survival data and two new rank order statistics arising in its consideration.

1966 • 7,595 citations

Bayesian Data Analysis

1995 • 2,837 citations

Modern Applied Statistics with S-PLUS

1999 • 952 citations

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

2001 • 877 citations

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

1994 • 299 citations

Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

2001 • 278 citations

Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy

1997 • 238 citations

Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome

1999 • 202 citations

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

2001 • 195 citations

Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome

1999 • 180 citations

Comparison of idarubicin + ara-C–, fludarabine + ara-C–, and topotecan + ara-C–based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

2001 • 169 citations

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF

1992 • 154 citations

Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.

1997 • 130 citations

New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.

1996 • 127 citations

Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials

1998 • 118 citations

How I treat older patients with AML

2000 • 112 citations

How I treat older patients with AML

2000 • 101 citations

Deleted Work

1955 • 0 citations